Paperback

$200.00
View All Available Formats & Editions
Choose Expedited Shipping at checkout for delivery by Friday, June 18

Overview

Nanoformulation Strategies for Cancer Treatment provides an up-to-date review on current developments and regulatory and clinical challenges in the field of nanopharmaceuticals and the effective treatment of diverse varieties of cancer. This important reference source is ideal for biomaterials scientists and pharmaceutical scientists working in the area of cancer diagnosis and therapy. Due to the high cost of traditional cancer treatment types, researchers have increasingly looked for new ways to augment the therapeutic performance of existing drug candidates. The use of nanotechnology-based approaches have gained significant momentum, thus leading to the launch of a series of new drug products.

As nanopharmaceuticals improve the therapeutic performance of cancer therapy drugs, but also provide opportunities for site-specific drug targeting in tumors, this work is a welcomed resource on the topics discussed.

  • Highlights the application of nanoformulations, including liposomes, nanoparticles and nanobiomaterials for targeted drug delivery to cancer cells
  • Explores recent advances made using novel nanoformulations containing herbal drugs and biotechnology based therapeutic strategies for cancer treatment
  • Assesses the regulatory hurdles that are necessary for the successful clinical translation of nanomedicines from the laboratory into the market

Product Details

ISBN-13: 9780128210956
Publisher: Elsevier Science
Publication date: 12/08/2020
Series: Micro and Nano Technologies Series
Pages: 402
Product dimensions: 7.50(w) x 9.25(h) x 0.82(d)

About the Author

Sarwar Beg is Assistant Professor at Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. Prior to joining Jamia Hamdard, Dr. Sarwar was worked with Jubilant Generics Limited, Noida, as Research Scientist and was responsible for QbD implementation in formulation and analytical development of generic products. He has over a decade of experience in the field of pharmaceutics, especially in the systematic development and characterization of novel and nanostructured drug delivery systems employing Quality by Design (QbD), Design of Experiments (DoE) and multivariate statistical approaches. Besides, Dr. Sarwar has good knowledge in applying various other advanced computational tools like drug release kinetic modeling, pharmacokinetic modeling and in vitro/in vivo correlation (IVIVC) approaches for efficient development of drug products. Dr. Beg has participated and presented his research work at several conferences in USA, Canada, China, India, Bangladesh, and has earned several “Best Paper” awards.

Mahfoozur Rahman, PhD, is an Assistant Professor at the Department of Pharmaceutical Sciences, Faculty of Health Science, Sam Higginbottom University of Agriculture, Technology & Sciences (SHUATS), Allahabad, India. His major areas of research interest include development and characterization of nanosized drug delivery systems for inflammatory disorders including psoriasis, arthritis, neurodegenerative disorders and cancer, etc. Besides, he is also working on amalgamation of herbal medicinal plants with modern therapeutics in order to deliver a scientifically acceptable therapy for various diseases management. To date he has published over 100 publications in peer reviewed journals.

Dr. Hani Choudhry is an Associate Professor of Genomics and the Head of Cancer and Mutagenesis Unit at the King Fahd Center for Medical Research in King Abdulaziz University (KAU), Saudi Arabia. Dr. Choudhry completed his DPhil in Clinical Medicine in Prof. Sir Peter Ratcliffe (Nobel Laureate 2019)’s lab at the Wellcome Trust Center for Human Genetics, University of Oxford, UK. Dr. Choudhry has received a number of international and prestigious awards including two AACR Scholar-in-Training Award, the Susan G. Komen for the Cure Award, the ASHG/Charles J. Epstein Trainee Award for Excellence in Human Genetics Research (SF), the Professional Achievement Award and the National Cancer Research Institute (NCRI) Prize Award. He was awarded by the British Embassy and the UAE International Genetic Disorders Prevention Award- Scientific Excellence Award in GCC. Dr. Choudhry’s current scientific interests focus on developing genomic technologies, and the integration of both clinical and pathological information with data generated from high-throughput molecular techniques. His work addresses the impact of genome and epigenome heterogeneity on the biology and clinical behaviour of diseases. In addition, he is leading a number of initiatives on artificial intelligence (AI) powered genome and drug discovery.

Prof. Eliana B. Souto (Souto, E.B.) is affiliated with the Department of Pharmaceutical Technology of the Faculty of Pharmacy, University of Coimbra, Portugal. Eliana is graduated in Pharmaceutical Sciences from the same University (2000). She holds a Master’s Degree in Pharmaceutical Technology and Pharmacotechnique from the Faculty of Pharmacy, University of Porto (2002), and the PhD in Pharmaceutical Technology, Biopharmaceutics and Biotechnology from the Institut für Pharmazie der Freie Universitaet Berlin, Germany (2005). Since August 2012, Eliana Souto holds the Habilitation Degree from the University Fernando Pessoa (Porto). Her research lines focus on the design, development, and characterization of new drug delivery systems. Other research interests include the controlled delivery of drugs across biological barriers, with especial emphasis for brain, ocular and skin administration. Eliana Souto is Associate Editor, member of the Editorial Board, and reviewer of several international scientific journals. She counts with 5 patents and more than 400 scientific publications in the field of Nanosciences and Nanotechnologies.

Professor Farhan Jalees Ahmad, is currently a Professor, School of Pharmaceutical Education & Research, and Dean, Interdisciplinary Sciences, Jamia Hamdard, New Delhi, India is an internationally known researcher in the area of Pharmaceutical Sciences. Having obtained his degree in M.Pharma and Ph.D (Medicine) from Jamia Hamdard, he continues to teach and leads a very productive research group which has been funded extensively by National and international funding agencies. He has earned many accolades including Young Scientist Fast Track from DST, Scientist of the Year-2005 from NESA, UGC Research Award 2011, Bharat Jyoti Award 2011, Pharma Ratan 2017, ABAP Senior Scientist Award 2017 and also prizes in scientific poster session in National Pharmacy Symposium. He has a US patent, Two PCT and 24 Indian patents to his name. He has published more than 300 research and review papers, 12 Book chapters, 9 books with a total citation of 9000, H Index of 44 and i-10 index of 200and attended many national and international conferences for presentation of research papers.Professor Farhan Jalees Ahmad, is currently a Professor, School of Pharmaceutical Education & Research, and Dean, Interdisciplinary Sciences, Jamia Hamdard, New Delhi, India is an internationally known researcher in the area of Pharmaceutical Sciences. Having obtained his degree in M.Pharma and Ph.D (Medicine) from Jamia Hamdard, he continues to teach and leads a very productive research group which has been funded extensively by National and international funding agencies. He has earned many accolades including Young Scientist Fast Track from DST, Scientist of the Year-2005 from NESA, UGC Research Award 2011, Bharat Jyoti Award 2011, Pharma Ratan 2017, ABAP Senior Scientist Award 2017 and also prizes in scientific poster session in National Pharmacy Symposium. He has a US patent, Two PCT and 24 Indian patents to his name. He has published more than 300 research and review papers, 12 Book chapters, 9 books with a total citation of 9000, H Index of 44 and i-10 index of 200and attended many national and international conferences for presentation of research papers.

Table of Contents

Section A: General consideration on cancer nanomedicines 1. Nanomedicine for combinational anticancer drug therapeutics: Recent advances, challenges and future perspectives 2. Market research in cancer therapeutics: New and Generic Product Development 3. Regulatory perspectives of nanomedicines for cancer treatment

Section B: Formulation technologies in cancer nanomedicines 4. Biopharmaceutical challenges in using lipid nanoparticles for oral chemotherapy 5. Polymeric nanoparticles for potential drug delivery applications in cancer 6. Lipid-polymer hybrid nanoparticles: Production, characterization and formulation of nucleic acids for cancer therapy 7. Metallic nanoparticles in drug delivery and cancer treatment 8. Liposomal nanotherapeutics in cancer treatment 9. Surface decoration strategies in nanomedicines for cancer treatment 10. Protein based nanomedicines as anticancer drug delivery platform 11. Phyto actives loaded nanocarriers for liver cancer treatment

Section C: Innovative treatment strategies in cancer nanomedicines 12. Nanotechnology assisted medical devices in cancer treatment 13. Immunotherapy as a boon in cancer treatment 14. Antibody-drug combination therapy in cancer treatment 15. Immune-chemo combination therapy in cancer treatment

Section D: Clinical perspectives in cancer nanomedicines 16. Formulation and biological stability of the nanomedicines in cancer treatment 17. Nanotoxicology profiling of cancer nanomedicines 18. Clinical translation status of nanoformulations

Section E: Regulatory perspectives in cancer nanomedicines 19. GLP and cGMP requirements in the development of cancer nanomedicines 20. Quality by Design approach for systematic development of nanopharmaceutical products

Customer Reviews